Login
Companies $ATYR
$5.24 +$0.00 (0.0%) After hours
aTYR PHARMA INC logo

aTYR PHARMA INC

atyrpharma.com

What Do They Do?

Develops biologic drug candidates for interstitial lung disease and other fibrotic and inflammatory diseases, including efzofitimod for pulmonary sarcoidosis and systemic sclerosis-related lung disease.

How Do They Make Money?

Partners pay through upfront and milestone payments for development and commercialization rights, with royalties on product sales; the company may also receive payment for research and development services over time.

FY2025 revenue

Who Are Their Customers?

The company licenses efzofitimod rights to a pharmaceutical partner for development and commercialization in Japan; the partner funds activities there. The company also supplies drug product and supports development.

Do Revenues Turn Into Profits?

No. It lost $74.1M in FY2025.

Operating income, FY2025
−40856% of revenue
▼ −14% (Loss) vs FY2024 (−$67.9M, −28900%)
Net income, FY2025
−39009% of revenue
▼ −16% (Loss) vs FY2024 (−$64M, −27244%)
Free cash flow, FY2025
−32665% of revenue
▲ +10% (Loss) vs FY2024 (−$69.2M, −29440%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $190K in Q3 FY2025
Net income
▲ +29% (Loss)
vs −$25.7M in Q3 FY2025
  • Sep 24, 2026 FDA aligned with aTyr on a new Phase 3 study design The study will test efzofitimod in pulmonary sarcoidosis, using lung function as its primary endpoint.
  • Jul 30, 2026 Efzofitimod Japan rights reverted to aTyr after the Kyorin agreement ended aTyr now holds the right to develop and commercialize efzofitimod globally.

Added a commercial-transition goal The latest report adds plans to move from clinical-stage biotechnology toward a commercial pharmaceutical company and begin U.S. pre-commercialization efforts; the older report described clinical development and pipeline expansion.

Who Do They Compete With?

Competes with Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Merck &, Sanofi-Aventis, GSK, and United Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support